Dr. David Spigel: Which Lung Cancer Patients Should We Be Doing Molecular Marker Testing For, and Should We Do "Reflex Testing"?

Article

Dr. David Spigel, Sarah Cannon Cancer Center, reviews which patients with lung cancer he feels should undergo molecular testing, as well as describing the potential value of immediate, reflex testing for molecular targets.

[powerpress]

Dr. Geoffrey Oxnard on Managing Acquired Resistance to EGFR Inhibitor Therapy (and Probably Crizotinib, Too)

Article

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes a wide range of options for best managing patients with advanced NSCLC who experience acquired resistance, the progression of cancer after a good initial response to a targeted therapy.

[powerpress]

Dr. Bob Doebele: Will We Be Able to Use Molecular Markers and Apply Targeted Therapies to Broader Lung Cancer Subtypes in the Near Future?

Article

Dr. Bob Doebele from the University of Colorado offers his perspective on whether targeted therapies will be able to applied to broader populations of patients with advanced NSCLC than those primarily with minimal smoking histories and an adenocarcinoma.

[powerpress]

Drs. Ross Camidge and Corey Langer: Who Do You Recommend Repeat Biopsy for if There Isn’t Enough Tissue for Molecular Testing?

Article

Drs. Ross Camidge and Corey Langer discuss which patients with advanced NSCLC they would recommend should have a repeat biopsy if their initial tissue sample doesn't have sufficient tissue for molecular testing.

[powerpress]

Dr. Heather Wakelee: How Should We Use Molecular Marker Information for Management of Earlier Stage Non-Small Cell Lung Cancer?

Article

Dr. Heather Wakelee from Stanford University discusses the open question of whether patients with resectable or locally advanced NSCLC should have testing for molecular markers, as well as how we might use this information in clinical practice.

 [powerpress]

Subscribe to Basic Cancer Info